{"preliminary_commentary":{"by_channel":{"x_thread":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"COG-AHOD0431","nct_id":"NCT00302003","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cog-ahod0431-nct00302003. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Treatment consists of 3 cycles of Doxorubicin hydrochloride IV (25 mg/m2) days 1 \\& 2, Vincristine sulfate IV (1.4 mg/m2 \\[max 2.8 mg\\]) Days 1 \\& 8, Prednisone orally (40 mg/m2) Days 1-7, Cyclophosphamide IV (600 mg/m2) Days 1 \\& 2, Filgrastim by mouth or IV (5 micrograms/kg/dose) 24 hours after Cyclophosphamide complete. See detailed description for remainder of therapy.","label":"Doxorubicin, Vincristine, Cyclophosphamide and Filgrastim","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2019-06-30","type":"ACTUAL"},"conditions":["Childhood Favorable Prognosis Hodgkin Lymphoma","Childhood Lymphocyte Depletion Hodgkin Lymphoma","Childhood Mixed Cellularity Hodgkin Lymphoma","Childhood Nodular Sclerosis Hodgkin Lymphoma","Stage I Childhood Hodgkin Lymphoma","Stage II Childhood Hodgkin Lymphoma"],"enrollment":{"count":287,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"radiation therapy","otherNames":["irradiation","radiotherapy","therapy, radiation"],"type":"RADIATION"},{"name":"doxorubicin hydrochloride","otherNames":["ADM","ADR","Adria","Adriamycin PFS","Adriamycin RDF"],"type":"DRUG"},{"name":"vincristine sulfate","otherNames":["leurocristine sulfate","VCR","Vincasar PFS"],"type":"DRUG"},{"name":"prednisone","otherNames":["DeCortin","Deltra"],"type":"DRUG"},{"name":"cyclophosphamide","otherNames":["CPM","CTX","Cytoxan","Endoxan","Endoxana"],"type":"DRUG"},{"name":"ifosfamide","otherNames":["Cyfos","Holoxan","IFF","IFX","IPP"],"type":"DRUG"},{"name":"vinorelbine tartrate","otherNames":["Eunades","navelbine ditartrate","NVB","VNB"],"type":"DRUG"},{"name":"dexamethasone","otherNames":["Aeroseb-Dex","Decaderm","Decadron","DM","DXM"],"type":"DRUG"},{"name":"etoposide phosphate","otherNames":["ETOP","Etopophos"],"type":"DRUG"},{"name":"cisplatin","otherNames":["CACP","CDDP","CPDD","DDP"],"type":"DRUG"},{"name":"cytarabine","otherNames":["ARA-C","arabinofuranosylcytosine","arabinosylcytosine","Cytosar-U","cytosine arabinoside"],"type":"DRUG"},{"name":"filgrastim","otherNames":["G-CSF","Neupogen"],"type":"BIOLOGICAL"}],"last_update":"2021-03-30","lead_sponsor":"Children's Oncology Group","official_title":"A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2012-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Event Free Survival Without Receiving Radiation Therapy (EFSnoRT).","timeFrame":"At 60 months"},{"measure":"Intensive Therapy Free Survival (ITFS).","timeFrame":"At 60 months"},{"measure":"Event Free Survival (EFS)","timeFrame":"At 60 months"}],"references":[{"citation":"Castellino SM, Giulino-Roth L, Harker-Murray P, Kahn JM, Forlenza C, Cho S, Hoppe B, Parsons SK, Kelly KM; COG Hodgkin Lymphoma Committee. Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30580. doi: 10.1002/pbc.30580. Epub 2023 Jul 28.","pmid":"37505794","type":"DERIVED"},{"citation":"Parekh A, Keller FG, McCarten KM, Kessel S, Cho S, Pei Q, Wu Y, Castellino SM, Constine LS, Schwartz CL, Hodgson D, Kelly KM, Hoppe BS. Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis. Blood. 2022 Sep 8;140(10):1086-1093. doi: 10.1182/blood.2022016098.","pmid":"35763667","type":"DERIVED"}],"start_date":{"date":"2006-02"},"study_type":"INTERVENTIONAL","title":"Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma","url":"https://clinicaltrials.gov/study/NCT00302003"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cog-ahod0431-nct00302003"}